Alexion Pharmaceuticals, Inc. [ALXN] took an upward turn with a change of 6.02%, trading at the price of $113.89 during the trading session on . The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. During the last trading session 4.29 million shares changed hands being bought and sold, while Alexion Pharmaceuticals, Inc. shares have an average trading volume of 1.83M shares for that time period. ALXN monthly volatility recorded 2.90%, in the meanwhile having share price volatility for the week set at 4.25%. PS value for ALXN stocks is 5.37 with PB recorded at 2.45.
Alexion Pharmaceuticals, Inc. [NASDAQ:ALXN]: Analyst Rating and Earnings
Its stock price has been found in the range of 92.56 to 141.86. This is compared to its latest closing price of $107.42.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Mon 3 Feb (In 57 Days).
Fundamental Analysis of Alexion Pharmaceuticals, Inc. [ALXN]
Now let’s turn to look at profitability: with a current Operating Margin for Alexion Pharmaceuticals, Inc. [ALXN] sitting at +39.24 and its Gross Margin at +83.34, this company’s Net Margin is now 31.00%. These measurements indicate that Alexion Pharmaceuticals, Inc. [ALXN] is generating considerably more profit, after expenses are accounted for, compared to its market peers.
This company’s Return on Total Capital is 13.43, and its Return on Invested Capital has reached 0.40%. Its Return on Equity is 0.86, and its Return on Assets is 0.56. These metrics show a mixed bag, which means that this investment’s attractiveness can be quickly increased or decreased in the short term, depending on future updates ALXN financial performance.
Turning to investigate this organization’s capital structure, Alexion Pharmaceuticals, Inc. [ALXN] has generated a Total Debt to Total Equity ratio of 34.99. Similarly, its Total Debt to Total Capital is 25.92, while its Total Debt to Total Assets stands at 23.02. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 14.51, and its Long-Term Debt to Total Capital is 31.23.
What about valuation? This company’s Enterprise Value to EBITDA is 13.30 and its Total Debt to EBITDA Value is 1.59. The Enterprise Value to Sales for this firm is now 5.71, and its Total Debt to Enterprise Value stands at 0.14. Alexion Pharmaceuticals, Inc. [ALXN] has a Price to Book Ratio of 2.37, a Price to Cash Flow Ratio of 51.31 and P/E Ratio of 17.45. These metrics show that this company has a mixed appeal, and ROI could be a gain or a loss.
Shifting the focus to workforce efficiency, Alexion Pharmaceuticals, Inc. [ALXN] earns $1,556,099 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.01 and its Total Asset Turnover is 0.30. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.48 and its Current Ratio is 2.88. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Alexion Pharmaceuticals, Inc. [ALXN] has 223.30M shares outstanding, amounting to a total market cap of $25.43B. Its stock price has been found in the range of 92.56 to 141.86. At its current price, it has moved down by -19.72% from its 52-week high, and it has moved up 23.04% from its 52-week low.
This stock’s Beta value is currently 1.68, which indicates that it is 4.25% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 57.76. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Alexion Pharmaceuticals, Inc. [ALXN] a Reliable Buy?
Shares of Alexion Pharmaceuticals, Inc. [ALXN], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.